News
Chasing Novartis, Amgen ushers Lp(a) drug into phase 3
Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move a
